361 related articles for article (PubMed ID: 8385484)
21. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
22. Yeast topoisomerase II is inhibited by etoposide after hydrolyzing the first ATP and before releasing the second ADP.
Morris SK; Lindsley JE
J Biol Chem; 1999 Oct; 274(43):30690-6. PubMed ID: 10521457
[TBL] [Abstract][Full Text] [Related]
23. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
24. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
[TBL] [Abstract][Full Text] [Related]
25. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.
DeVore RF; Corbett AH; Osheroff N
Cancer Res; 1992 Apr; 52(8):2156-61. PubMed ID: 1313738
[TBL] [Abstract][Full Text] [Related]
26. Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group.
Robinson MJ; Martin BA; Gootz TD; McGuirk PR; Osheroff N
Antimicrob Agents Chemother; 1992 Apr; 36(4):751-6. PubMed ID: 1323952
[TBL] [Abstract][Full Text] [Related]
27. DNA unknotting activity (DNA topoisomerase II) isolated from a thermophilic archaebacterium Sulfolobus is inhibited by novobiocin. Partial purification, identification of the two subunits and characteristics of the enzyme.
Assairi LM
Biochim Biophys Acta; 1994 Sep; 1219(1):107-14. PubMed ID: 8086447
[TBL] [Abstract][Full Text] [Related]
28. Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate.
Zechiedrich EL; Christiansen K; Andersen AH; Westergaard O; Osheroff N
Biochemistry; 1989 Jul; 28(15):6229-36. PubMed ID: 2551367
[TBL] [Abstract][Full Text] [Related]
29. Effect of casein kinase II-mediated phosphorylation on the catalytic cycle of topoisomerase II. Regulation of enzyme activity by enhancement of ATP hydrolysis.
Corbett AH; DeVore RF; Osheroff N
J Biol Chem; 1992 Oct; 267(28):20513-8. PubMed ID: 1328202
[TBL] [Abstract][Full Text] [Related]
30. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Rappa G; Lorico A; Sartorelli AC
Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186
[TBL] [Abstract][Full Text] [Related]
31. Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.
Strumberg D; Nitiss JL; Dong J; Walker J; Nicklaus MC; Kohn KW; Heddle JG; Maxwell A; Seeber S; Pommier Y
Antimicrob Agents Chemother; 2002 Sep; 46(9):2735-46. PubMed ID: 12183223
[TBL] [Abstract][Full Text] [Related]
32. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events.
Sørensen BS; Sinding J; Andersen AH; Alsner J; Jensen PB; Westergaard O
J Mol Biol; 1992 Dec; 228(3):778-86. PubMed ID: 1335085
[TBL] [Abstract][Full Text] [Related]
33. Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerases.
Huff AC; Kreuzer KN
J Biol Chem; 1990 Nov; 265(33):20496-505. PubMed ID: 2173709
[TBL] [Abstract][Full Text] [Related]
34. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase II-mediated cleavage of plasmid DNA.
Burden DA; Froelich-Ammon SJ; Osheroff N
Methods Mol Biol; 2001; 95():283-9. PubMed ID: 11089240
[No Abstract] [Full Text] [Related]
36. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
Biochemistry; 2000 Mar; 39(10):2726-32. PubMed ID: 10704224
[TBL] [Abstract][Full Text] [Related]
37. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus.
Yamashita Y; Kawada S; Fujii N; Nakano H
Biochemistry; 1991 Jun; 30(24):5838-45. PubMed ID: 1646001
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells.
Bandele OJ; Osheroff N
Biochemistry; 2008 Nov; 47(45):11900-8. PubMed ID: 18922022
[TBL] [Abstract][Full Text] [Related]
39. Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage.
Fortune JM; Osheroff N
J Biol Chem; 1998 Jul; 273(28):17643-50. PubMed ID: 9651360
[TBL] [Abstract][Full Text] [Related]
40. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
Cline SD; Macdonald TL; Osheroff N
Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
